Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | SVP, CHIEF FINANCIAL OFFICER | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
HALOZYME THERAPEUTICS, INC.
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 38,494 |
Ending reported balance
After 2026-02-23 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 5,332 · Balance 38,290 Row 2 · 2026-02-20 · Tax withholding · Disposed 2,876 · Balance 35,414 F1: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Row 3 · 2026-02-23 · Exercise / conversion · Acquired 6,688 · Balance 42,102 Row 4 · 2026-02-23 · Tax withholding · Disposed 3,608 · Balance 38,494 F2: The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 15,995 |
Reported balance
After 2026-02-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-02-20 · Exercise / conversion · Disposed 5,332 · Balance 15,995 F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
| Performance Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 36,357 |
Reported balance
After 2026-02-23 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-02-23 · Exercise / conversion · Disposed 6,688 · Balance 36,357 F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported disposition of 2,876 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F2: The reported disposition of 3,608 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
F3: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 22, 2024 Filed Jul 23, 2024 20:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,008 | $53.85 | $215,842.82 |
DisclosureSEC source: 0001415889-24-019936 · form4-07232024_080706.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,480 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $53.17 to $54.15. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| July 22, 2024 Filed Jul 23, 2024 20:37 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 4,008 | $22.50 | $90,180.00 |
DisclosureSEC source: 0001415889-24-019936 · form4-07232024_080706.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,488 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · derivative · entry 9 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 10,000 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F5 · derivative.exercise_date: This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $52.04 | $520,400.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · nonDerivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,480 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F4 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $51.52 to $52.36. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 28, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $22.50 | $225,000.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · nonDerivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · derivative · entry 8 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 10,000 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F5 · derivative.exercise_date: This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $51.93 | $519,340.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,480 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F3 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $51.66 to $52.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 27, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $22.50 | $225,000.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionOption to Purchase Common Stock · Derivative | 10,000 | $0.00 Strike: $22.50 | $0.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · derivative · entry 7 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 10,000 shares Expires 2025-07-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F5 · derivative.exercise_date: This option was granted on July 1, 2015 and vested one-fourth on the first anniversary of such date and then 1/48th monthly thereafter. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 10,000 | $51.82 | $518,200.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,480 F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. F2 · price: Represents a weighted average sales price per share. These shares were sold at prices ranging from $51.605 to $52.06. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 10,000 | $22.50 | $225,000.00 |
DisclosureSEC source: 0001415889-24-018408 · form4-06282024_080653.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,480 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The option exercises and sales reported on this Form 4 were effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person on March 22, 2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 26,751 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-005539 · form4-02272024_100224.xml · derivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,751 Underlying: Common Stock · 26,751 shares Expires not disclosed F2 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F2 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 22:05 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 27,722 | $0.00 Strike: $40.56 | $0.00 |
DisclosureSEC source: 0001415889-24-005539 · form4-02272024_100224.xml · derivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,722 Underlying: Common Stock · 27,722 shares Expires 2034-02-23 F1 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,329 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004475 · form4-02202024_110227.xml · derivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,987 Underlying: Common Stock · 5,329 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,093 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004475 · form4-02202024_110227.xml · derivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,186 Underlying: Common Stock · 5,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,864 | $36.10 | $103,390.40 |
DisclosureSEC source: 0001415889-24-004475 · form4-02202024_110227.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,480 F2 · shares: The reported disposition of 2,864 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,329 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004475 · form4-02202024_110227.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,344 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 2,737 | $36.10 | $98,805.70 |
DisclosureSEC source: 0001415889-24-004475 · form4-02202024_110227.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,015 F1 · shares: The reported disposition of 2,737 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2024 Filed Feb 20, 2024 23:53 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,093 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004475 · form4-02202024_110227.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,752 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004185 · form4-02162024_100244.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,254 Underlying: Common Stock · 1,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 686 | $35.91 | $24,634.26 |
DisclosureSEC source: 0001415889-24-004185 · form4-02162024_100244.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,659 F1 · shares: The reported disposition of 686 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 15, 2024 Filed Feb 16, 2024 22:41 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-004185 · form4-02162024_100244.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 21:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 2,502 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003525 · form4-02132024_090242.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,502 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 21:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,477 | $35.49 | $52,418.73 |
DisclosureSEC source: 0001415889-24-003525 · form4-02132024_090242.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,091 F1 · shares: The reported disposition of 1,477 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2024 Filed Feb 13, 2024 21:15 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,502 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-003525 · form4-02132024_090242.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 21,316 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002954 · form4-02222023_120245.xml · derivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,316 Underlying: Common Stock · 21,316 shares Expires not disclosed F4 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. F4 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary date thereafter. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 61,061 | $0.00 Strike: $49.26 | $0.00 |
DisclosureSEC source: 0001415889-23-002954 · form4-02222023_120245.xml · derivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,061 Underlying: Common Stock · 61,061 shares Expires 2033-02-16 F3 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 5,094 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002954 · form4-02222023_120245.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,279 Underlying: Common Stock · 5,094 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 2,525 | $49.26 | $124,381.50 |
DisclosureSEC source: 0001415889-23-002954 · form4-02222023_120245.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,066 F1 · shares: The reported disposition of 2,525 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 16, 2023 Filed Feb 22, 2023 00:00 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 5,094 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002954 · form4-02222023_120245.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,591 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 11:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 1,254 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002712 · form4-02172023_110222.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,508 Underlying: Common Stock · 1,254 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 11:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 621 | $49.20 | $30,553.20 |
DisclosureSEC source: 0001415889-23-002712 · form4-02172023_110222.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,497 F1 · shares: The reported disposition of 621 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 11:25 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,254 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002712 · form4-02172023_110222.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,118 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2023 Filed Feb 14, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 1,389 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002511 · form4-02142023_100247.xml · derivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 12, 2023 Filed Feb 14, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 681 | $48.92 | $33,314.52 |
DisclosureSEC source: 0001415889-23-002511 · form4-02142023_100247.xml · nonDerivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,864 F2 · shares: The reported disposition of 681 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 12, 2023 Filed Feb 14, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,389 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002511 · form4-02142023_100247.xml · nonDerivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 2,503 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002511 · form4-02142023_100247.xml · derivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,502 Underlying: Common Stock · 2,503 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F3 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 1,392 | $48.92 | $68,096.64 |
DisclosureSEC source: 0001415889-23-002511 · form4-02142023_100247.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,156 F1 · shares: The reported disposition of 1,392 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 22:21 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 2,503 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002511 · form4-02142023_100247.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,548 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 365 | $53.69 | $19,596.85 |
DisclosureSEC source: 0001415889-22-011459 · form4-11172022_121159.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,045 Read SEC document |
| November 15, 2022 Filed Nov 17, 2022 00:51 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | SaleCommon Stock | 4,635 | $53.82 | $249,455.70 |
DisclosureSEC source: 0001415889-22-011459 · form4-11172022_121159.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, CHIEF FINANCIAL OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,410 Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantRestricted Stock Units · Derivative | 20,373 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001393 · edgar.xml · derivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,373 Underlying: Common Stock · 20,373 shares Expires not disclosed F4 · derivative.exercise_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. F4 · derivative.expiration_date: This award vests one-fourth on the first anniversary of the grant date and then one-fourth on each anniversary thereafter. Read SEC document |
| February 16, 2022 Filed Feb 17, 2022 23:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 62,315 | $0.00 Strike: $34.36 | $0.00 |
DisclosureSEC source: 0001179110-22-001393 · edgar.xml · derivative · entry 4 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,315 Underlying: Common Stock · 62,315 shares Expires 2032-02-16 F3 · derivative.exercise_date: This option vests one-fourth on such date and then 1/48th monthly thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 1,255 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001393 · edgar.xml · derivative · entry 3 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,762 Underlying: Common Stock · 1,255 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F2 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 433 | $34.43 | $14,908.19 |
DisclosureSEC source: 0001179110-22-001393 · edgar.xml · nonDerivative · entry 2 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,045 F1 · shares: The reported disposition of 433 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 23:03 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,255 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001393 · edgar.xml · nonDerivative · entry 1 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Unit · Derivative | 1,256 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · derivative · entry 9 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,256 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Tax withholdingCommon Stock | 427 | $33.64 | $14,364.28 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · nonDerivative · entry 6 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,223 F3 · shares: The reported disposition of 427 shares represents the shares that were withheld by the issuer as payment for minimum statutory tax withholding obligations. Read SEC document |
| February 14, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionCommon Stock | 1,256 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · nonDerivative · entry 5 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,650 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 12, 2022 Filed Feb 15, 2022 00:28 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | Exercise / conversionRestricted Stock Units · Derivative | 1,389 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-22-001200 · edgar.xml · derivative · entry 8 LaBrosse Nicole · CIK 0001910662 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,389 Underlying: Common Stock · 1,389 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. F4 · derivative.expiration_date: This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.